Celanese targets $700M-$800M 2027 free cash flow as cost and interest savings build

• “The team is really being very intentional about how we engage with customers right now to finish the year so we can plan and position for what is still some uncertainty as we go into 2027,” said President, CEO & Director Scott Richardson, describing Acetyls as focused on “contracting business” for 2027 and Engineered Materials as “being really deliberate and intentional with how we build the pipeline with high quality.”

• “We’re demonstrating our capability to generate $700 million to $800 million of free cash flow in 2 very different environments in the last couple of years,” said Vice President of Investor Relations William Cunningham, adding, “we’re confident in this $700 million to $800 million range for next year,” and citing “no need to increase our CapEx” plus “opportunity in working capital” because “inventory values… are still elevated.”

• “With the cost and actions that we’ve already done in both Engineered Materials and Acetyl Chain, we’re seeing right now $70 million flow through this year,” said Senior VP & CFO Chuck Kyrish. “We have another $30 million to $40 million that will hit us next year in cost savings,” he added, and “we also do expect interest expense savings to begin, and that’s $40 million on a net basis.”

Outlook

• “We feel that $700 million to $800 million is really the right range for next year,” said William Cunningham, tying the framework to CapEx discipline (“there’s really no need to increase our CapEx”) and restructuring cash outlays that “should continue to decline next year, call that $30 million to $40 million.”

• For Q4 seasonality assumptions, Scott Richardson said, “in Engineered Materials, I think we’ve got between about a 6% and 7% volume decline baked in the fourth quarter,” and in Acetyls, “it’s usually about a $25 million plus/minus decline from Q3 into Q4,” adding, “we are seeing pressure from raw materials… and… from the low Rhine water levels, and we’ve baked… both of those into that seasonality guide.”

• On inflation and productivity heading into 2027, Richardson said, “we are targeting $150 million of gross productivity to offset inflation going into 2027,” and added, “we’re going to push to do higher than that $150 million… because I do think we are going to continue to see inflationary pressures.”

Financial Results

• The transcript did not include consolidated Q3 revenue, EPS, EBITDA, margins, or cash flow figures; management instead discussed drivers affecting Q4 and 2027.

• Scott Richardson described Q4 Acetyls bridge items in Asia: “We’ve got an unexpected turnaround from one of our key pipeline suppliers in China… having to take an extended outage… unplanned,” adding, “we are running at lower rates here in the quarter because of that outage,” and “we do have margins coming off through the quarter… and that’s what we’ve embedded into the guidance.”

• Chuck Kyrish updated a prior nylon optimization item: “That $45 million, let’s call it, closer to maybe $30 million for this year,” and added, “we’re still looking at 2027 and action plans there.”

Q&A

• Ghansham Panjabi, Baird: asked about the EBITDA assumptions behind 2027 free cash flow; Scott Richardson answered, “pushing approximately $100 million between cost and interest next year… we do feel like we can make 2026 a base… going into 2027,” and William Cunningham added, “we’re confident in this $700 million to $800 million range for next year.”

• Patrick Cunningham, Citi: asked about downstream derivatives capacity and Asian disruption risk; Scott Richardson answered, “there could be a need for additional investment,” but “we still believe… our capital will fall between the $300 and $350 million,” and said downstream differentiation “provides us with a little more resiliency… particularly out of China.”

• Jeffrey Zekauskas, JPMorgan: asked about EU VAM tariff changes and auto/nylon; Scott Richardson said tariffs were “not… material at this point,” and on autos, “our volumes are down this year in automotive, largely driven by China,” while on nylon, “margins have significantly improved.”

• Kevin McCarthy, Vertical Research: asked about Ibn Sina volatility and Nutrinova proceeds; Scott Richardson said Ibn Sina is a “natural hedge,” noted it is “on a 1-quarter lag,” and on Nutrinova, “we’re going to get a little over $150 million of proceeds,” adding the remaining divestiture target is “likely a series of transactions.”

• Vincent Andrews, Morgan Stanley: asked about seasonality and robotics; Scott Richardson said robotics is “not just about one product… [but] a multiproduct offering,” and added, “we are excited… about areas like robotics,” while Q4 seasonality assumptions were “very similar to what we’ve seen historically.”

• Hassan Ahmed, Alembic: asked about methanol and 2027 EBITDA tailwinds; Scott Richardson said methanol integration remains “about 40% to 50%,” described Q3 as “margin compression” early then “margin expansion… as we exited the quarter,” and Chuck Kyrish quantified cost/interest savings as “$30 million to $40 million” next year plus “$40 million” net interest savings.

• Joshua Spector, UBS: asked about EM price/cost and supply; Scott Richardson said the team is “very focused on price,” adding raw materials “are going to flow through in Q1,” and on competition, “we’ve seen more competition on the standard grades… added in Asia.”

Sentiment Analysis

• Analysts’ tone was slightly negative to pressing, focused on cash flow underpinnings, volatility, and competitive risk, including questions on “what you’re assuming” for free cash flow (Baird), “risk… disrupted by Asian supply” (Citi), and whether differentiation can hold against “potential supply out of China” (UBS).

• Management tone was slightly positive but cautionary on near-term uncertainty, repeatedly pointing to variability and embedded conservatism, including “some uncertainty as we go into 2027” (President, CEO & Director Richardson) and “we’ve baked in margin compression” (President, CEO & Director Richardson), while expressing confidence via “we’re confident in this $700 million to $800 million range for next year” (Vice President of Investor Relations Cunningham).

• Versus the prior quarter, management used more explicit caution language around volatility (e.g., “dynamic” and “uncertainty”), while still emphasizing controllable levers like productivity and working capital.

Quarter-over-quarter comparison

• Q3 added a firmer 2027 free cash flow framing, with management reiterating “$700 million to $800 million… for next year” (Vice President of Investor Relations Cunningham); in Q2, Chuck Kyrish described $700 million to $800 million as a “baseline sustainable level” while discussing 2026 confidence.

• Q3 put more weight on Asia-specific operational disruptions and Europe cost frictions, including “unexpected… outage… in China” and “pressure… from the low Rhine water levels” (President, CEO & Director Richardson); Q2 focused more on supply-chain normalization and portfolio/footprint actions (including Frankfurt restart and Lanaken acceleration).

• Analysts’ focus shifted from Q2’s emphasis on normalization/one-time impacts and leverage trajectory toward Q3’s emphasis on 2027 bridge items (free cash flow, cost/interest savings, and sustainability of electronics/medical momentum).

Risks and Concerns

• “We’ve got an unexpected turnaround… in China… extended outage,” Scott Richardson said, adding it caused “lower rates” and was embedded in guidance as “margins coming off through the quarter.”

• Richardson flagged Europe pressures: “energy costs in Europe” and “cost pressure in Europe from both energy as well as from the Rhine River levels.”

• On competitive supply, Richardson acknowledged “new capacities… added in Asia” and “more competition on the standard grades,” while positioning mitigation as footprint flexibility and a shift to “more differentiated applications.”

Final Takeaway

Celanese management centered the call on a 2027 cash generation framework, reiterating “$700 million to $800 million” of free cash flow and pointing to limited need for higher CapEx, working-capital opportunity from elevated inventories, declining restructuring cash outlays, and quantified cost and interest savings. At the same time, management embedded near-term caution around an unplanned China supplier outage, raw material and European energy/Rhine-related pressures, and ongoing competitive intensity in standard grades, while maintaining that electronics and medical demand tailwinds should continue into 2027.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.